Caraway Therapeutics, a biopharmaceutical company developing novel treatments for neurodegenerative and rare diseases, announced that the company has been awarded a second research grant from The Michael J. Fox Foundation to further investigate the role of TMEM175, a lysosomal ion channel genetically implicated in Parkinson’s disease.
Coding variants of TMEM175 have been linked to both incidence and age of onset of Parkinson’s disease. Decreased TMEM175 function reduces lysosomal efficiency in neuronal cells, which is strongly associated with Parkinson’s disease. Caraway Therapeutics will use the grant funding to further investigate the role of TMEM175 in disease models and evaluate the utility of TMEM175 agonists as therapeutics for Parkinson’s disease.
Read more about Caraway Therapeutics here.
Photo by Artem Kondratskyi
